Results 51 to 60 of about 28,079 (244)

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 ...
Daria J Hazuda
doaj   +1 more source

Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus

Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Islatravir‐loaded dissolving microarray patches (MAPs) provide a minimally invasive, long‐acting solution for HIV‐1 prevention and treatment. In rats, sustained islatravir delivery lasts up to three months, while in minipigs, efficacious plasma levels are detected for six days.
Qonita Kurnia Anjani, Ashley R. Johnson, Akmal H. Sabri, Ryan Lutz, Steven Tignor, Jeanine Ballard, Nathan Rudd, Li Zhao, Lalitkumar K. Vora, Stephanie E. Barrett, Angela Wagner, Ryan F. Donnelly   +11 more
wiley   +1 more source

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. [PDF]

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source

Molecular Epidemiology of HIV-1 in Eastern Europe and Russia

Viruses, 2022
The HIV epidemic in Eastern Europe and Russia is large and not well-controlled. To describe the more recent molecular epidemiology of HIV-1, transmitted drug resistance, and the relationship between the epidemics in this region, we sequenced the protease
Maarten A. A. van de Klundert, Anastasiia Antonova, Giulia Di Teodoro, Rafael Ceña Diez, Nikoloz Chkhartishvili, Eva Heger, Anna Kuznetsova, Aleksey Lebedev, Aswathy Narayanan, Ekaterina Ozhmegova, Alexander Pronin, Andrey Shemshura, Alexandr Tumanov, Nico Pfeifer, Rolf Kaiser, Francesco Saladini, Maurizio Zazzi, Francesca Incardona, Marina Bobkova, Anders Sönnerborg   +19 more
doaj   +1 more source

Characterization of HIV-1 Integrase Reactions with Viral DNA [PDF]

, 2013
HIV-1 integrase (integrase) catalyzes the insertion of viral DNA into human chromosomes and is a focus for development of anti-integrase inhibitors to combat HIV infection. Integrase catalyzes two steps, a DNA-end cleavage reaction (3’-processing), and a
Kettlewell, Joanna
core   +1 more source

Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns [PDF]

, 2017
Background: Persistent residual viremia (RV) and low grade inflammation and immune activation have been associated with non-AIDS defining events. The impact of persistent RV and HIV-DNA load on immune activation/ inflammation remains unclear.
Antonelli, Guido, Bon, Isabella, D'Ettorre, Gabriella, DE VITO, Corrado, Di Carlo, Daniele, Falasca, Francesca, Fantauzzi, Alessandra, Fimiani, Caterina, Mezzaroma, Ivano, Re, Maria Carla, Turriziani, Ombretta, Vullo, Vincenzo   +11 more
core   +2 more sources

Direct Access to α,β‐Unsaturated γ‐Lactams via Palladium‐Catalysed Carbonylation of Propargylic Ureas.

Advanced Synthesis &Catalysis, Volume 367, Issue 5, March 4, 2025.
Abstract Additive carbonylations typically necessitate strong nucleophiles, such as alcohols or amines. In this study, we carbonylated a poorly nucleophilic urea, under oxidant‐free conditions. Our straightforward carbonylative strategy enables access to versatile α,β‐unsaturated γ‐lactams featuring an aminocarbonyl fragment, utilizing readily ...
Debora Schiroli, Aleksandr Voronov, Francesco Pancrazzi, Nunzio Iraci, Salvatore Vincenzo Giofrè, Beatrice Macchi, Valeria Stefanizzi, Raffaella Mancuso, Bartolo Gabriele, Paolo Pio Mazzeo, Luca Capaldo, Nicola Della Ca'   +11 more
wiley   +1 more source

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]

, 2008
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy, Cahn, Cahn, Chokshi, Cleary, Cohen, Dayam, Esté, Ford, Ford, Jens van Roey, Khoo, Marzolini, Moran, Nathan, Nathan Ford, Pinheiro, Pozniak, Saag, Tido von Schoen-Angerer, Woodfall, World Health Organization, Yeni   +22 more
core   +2 more sources

Insights into the Dynamics and Binding Mechanisms of the Alkhumra Virus NS2B/NS3 Protease: A Molecular Dynamics Study

Advanced Theory and Simulations, EarlyView.
The ΔRMSF$\Delta {\rm RMSF}$ analysis reveals significant flexibility differences between free NS3 and the NS2B/NS3 complex, with notable deviations in specific regions. Key residues driving NS2B binding are identified, and the protonation state of catalytic serine affects oxyanion hole formation.
Jurica Novak, Shivananda Kandagalla, Ramesh Sistla   +2 more
wiley   +1 more source

LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV

EBioMedicine, 2016
Persistence of latent, replication-competent Human Immunodeficiency Virus type 1 (HIV-1) provirus is the main impediment towards a cure for HIV/AIDS (Acquired Immune Deficiency Syndrome). Therefore, different therapeutic strategies to eliminate the viral
Lenard S. Vranckx, Jonas Demeulemeester, Suha Saleh, Annegret Boll, Gerlinde Vansant, Rik Schrijvers, Caroline Weydert, Emilie Battivelli, Eric Verdin, Anna Cereseto, Frauke Christ, Rik Gijsbers, Zeger Debyser   +12 more
doaj   +1 more source